Combination Therapy Shows Potential in Psoriasis, Obesity
Overview
The TOGETHER-PsO trial demonstrated that ixekizumab plus tirzepatide significantly improved outcomes in adult patients with moderate to severe plaque psoriasis and obesity, achieving simultaneous complete skin clearance and at least 10% weight reduction at 36 weeks. The combination therapy outperformed ixekizumab alone in multiple efficacy endpoints.
Background
Psoriasis is a chronic inflammatory skin condition that can significantly impact quality of life, particularly in patients with comorbid obesity. The presence of obesity may reduce the effectiveness of psoriasis treatments, making it crucial to explore combination therapies that address both skin and weight management. The TOGETHER-PsO trial provides insights into the potential benefits of combining an IL-17A inhibitor with an anti-obesity agent.
Data Highlights
| Group | Primary Endpoint Achieved | PASI 100 | PASI 75 + 5% Weight Reduction | Weight Reduction ≥10% |
|---|---|---|---|---|
| Ixekizumab + Tirzepatide | 27% | 41% | 80% | 69% |
| Ixekizumab Alone | 6% | 29% | 18% | 9% |
Key Findings
- 27% of participants receiving ixekizumab plus tirzepatide achieved the primary endpoint compared to 6% with ixekizumab alone.
- 41% of the combination group achieved PASI 100 versus 29% in the ixekizumab group.
- Simultaneous PASI 75 and at least 5% weight reduction was observed in 80% of the combination group compared to 18% in the control group.
- Mean body weight decreased by 15% in the combination group versus 1% in the ixekizumab group.
- Gastrointestinal adverse events were more common in the combination therapy group, including nausea (25% vs 2%) and diarrhea (15% vs 2%).
- No new safety concerns were identified, with serious adverse events occurring in 4% of the combination group.
Clinical Implications
The findings suggest that combining ixekizumab with tirzepatide may offer a dual benefit for patients with psoriasis and obesity, enhancing treatment efficacy. Clinicians should consider this combination therapy for eligible patients to improve both skin clearance and weight management outcomes.
Conclusion
The TOGETHER-PsO trial supports the use of ixekizumab plus tirzepatide as a promising treatment strategy for patients with moderate to severe psoriasis and obesity, demonstrating significant improvements in key clinical outcomes.
Related Resources & Content
- Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial | Trials | JAMA Dermatology | JAMA Network, 2026 -- TOGETHER-PsO Trial Results
- Combo Therapy for Psoriasis With Obesity, Conexiant, 2026 -- Overview of TOGETHER-PsO Trial
- GLP-1 Agents May Reduce Psoriasis Severity, Conexiant, 2026 -- Review of GLP-1 RAs in Psoriasis
- Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks, Dermatology and Therapy, 2026 -- Study on Tildrakizumab
- conexiant — Dual Therapy Boosts Weight Loss in Trial
- Dual Therapy Boosts Weight Loss in Trial, Conexiant, 2026 -- Summary of Combination Therapy Benefits
- EuroGuiDerm/EDF Systemic Treatment Guideline, 2025 -- Recommendations for Psoriasis Management
- Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial | Trials | JAMA Dermatology | JAMA Network
- GLP-1RAs in patients with psoriasis | Hormones | Springer Nature Link
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
